Tyra Biosciences' TYRA-300, an oral FGFR3 inhibitor, showed promising efficacy but raised concerns with some FGFR1/2-driven adverse events, causing a significant stock drop. TYRA-300 demonstrated ...

The Tallest Dwarf” was a 92 minute documentary helmed by Julie Forrest Wyman, who directed and produced.  Debra Schaffner ...

FGFR3 mutations and HER2 positivity in bladder cancer guide treatment with erdafitinib and fam-trastuzumab deruxtecan-nxki, respectively. Emerging biomarkers such as KIM-1 in renal cell carcinoma and ...

Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to ...

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat ...

First — specifically in stage 4 disease — do I have a gene mutation? Do I have a gene mutation called FGFR3, because if you do, you can receive a medication called Balversa [erdafitinib]. [This agent] ...

The Journal of Urology Vol 212 1-8 Jul 2024. 6 Lotan et al., (2022). Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification.

Achondroplasia risk factors Achondroplasia is caused by a spontaneous mutation in a specific gene called FGFR3. About 98% of cases result from the exact same change in the DNA in this gene.

Tasurgratinib (also known as E-7090) is an oral selective FGFR1, FGFR2, and FGFR3 inhibitor that, if approved, will join other drugs in the class on the market, including Incyte’s Pemazyre ...

A year earlier ImmunoGen revealed that the alliance had yielded three candidates, including one ADC directed at fibroblast growth factor receptor 3 (FGFR3) associated with bladder and brain ...

In this video, Gopa Iyer, MD, shares the background and findings from the study, “A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in ...

LY3866288, an FGR3-specific inhibitor, led to an objective response in 42% of patients with metastatic urothelial carcinoma in a phase I study. The drug did not induce adverse events more commonly ...